# MILESTONE 5 MISS

Timestamp: 2026-05-27 06:00 UTC

Nominal checkpoint: Hour 10.

## Required State

The milestone required:

- intervention point selected,
- druggability and selectivity analyzed,
- lead-indication recommendation drafted,
- hostile critique round two completed.

## Why It Was Missed

The best intervention-point candidates were analyzed, but each failed a hard
gate:

- Surface/secreted/enzyme rescue: no `GO` candidate among 24 accessible targets.
  Top parked comparators were `ITGAM`, `CD44`, `CD274`, `ITGAX`, `TYROBP`,
  `CD24`, `MSR1`, `LILRB2`, `SIRPA`, `GPNMB`, and `CHI3L1`.
- Treatment-response stratification: no corrected baseline predictor in
  `GSE138746` RA anti-TNF or `GSE253006` UC tofacitinib. The best RA nominal
  result had FDR `0.6056`; UC baseline minimum FDR was `0.976`.
- Pharmacodynamic branch: UC tofacitinib and psoriasis secukinumab showed only
  weak or nominal post-treatment module decreases. These are comparator
  signals, not target nominations.
- Foundation-model branch: no strict candidate survived both relative
  Geneformer support and real perturbation validation.

## Current Position

No therapeutic-relevant V3 claim satisfies the Definition of Done.

The recurring module is likely real enough to continue pursuing, but current
evidence says the naive intervention points are mostly:

- saturated prior art,
- inaccessible intracellular marker proteins,
- broad immune suppressors,
- confounded myeloid-abundance markers,
- or repair-associated genes where the available drug modality points in the
  wrong direction.

## Immediate Route Around The Miss

Wave19 will search outside the already-demoted target classes:

1. Tolerogenic checkpoint controllers that act upstream of APC activation but
   are not simply PD-L1/CD47/galectin/Fc/complement repeats.
2. Lysosomal stress regulators where activation or restoration can be modeled
   and where existing chemical matter is not automatically disqualifying.
3. A hostile-review branch to decide whether the correct conclusion is that the
   cross-autoimmune module is a biomarker of tissue damage rather than a causal
   intervention axis.

This is a miss, not exhaustion; the session continues.
